President Trump escalated his trade agenda on April 2 by imposing major tariffs on imported patented pharmaceuticals and their ingredients. The policy is designed to push drugmakers to manufacture in the United States and agree to “most favored nation” pricing so Americans pay less for prescription drugs.
Companies that refuse both goals could face a 100% tariff, while those that invest in U.S. factories may receive reduced or even zero tariffs. Generic drugs are largely untouched, limiting the impact on most prescriptions.
The administration argues the move will improve national security and reduce dependence on foreign suppliers such as China and India. Critics warn that some brand-name drug prices could rise before new factories and pricing deals take effect.
Trump signed a new tariff order hitting imported brand-name drugs with up to a 100% duty unless drugmakers lower U.S. prices and move production home. Generics are mostly exempt, and firms that build in America can avoid the penalty. #Trump #Tariffs #BigPharma #DrugPrices pic.twitter.com/RqE96Ze4OO
— Matthew Brady (@mattbrady775) April 3, 2026
- On April 2, 2026, President Donald Trump signed an executive order imposing tariffs of up to 100% on certain imported patented drugs and their active pharmaceutical ingredients under Section 232 of the Trade Expansion Act of 1962. The White House says the move is intended to reduce U.S. dependence on foreign drug manufacturing and strengthen national security.
- The full 100% tariff applies to companies that neither agree to “most favored nation” (MFN) pricing nor actively move production into the United States. MFN pricing means Americans would pay no more than consumers in other wealthy countries.
- Companies that both sign MFN agreements and build U.S. manufacturing facilities can receive a 0% tariff rate. Companies with approved plans to onshore production but without a pricing deal will face a 20% tariff, which rises to 100% on April 2, 2030.
- The tariffs take effect in 120 days for large pharmaceutical companies and 180 days for smaller firms, giving them time to negotiate with the administration or begin construction of domestic plants.
- Generic drugs, which account for roughly 90% of U.S. prescriptions, are exempt. Additional carveouts may apply to orphan drugs, animal-health products, cell and gene therapies, and products from certain trade-partner countries.
- Existing trade agreements create lower rates for some countries: 15% for the EU, Japan, South Korea, Switzerland and Liechtenstein, while the U.K. receives a 10% rate that could later fall to zero.
- The administration says 13 to 17 drug companies, including firms such as Pfizer, Eli Lilly, and AstraZeneca, have already agreed to pricing deals or U.S. investment plans, helping them avoid the highest tariff.
- Critics, including industry groups and some economists, argue the tariffs could temporarily increase costs for branded medicines if drugmakers pass the higher import costs to consumers or insurers.
